



Europass Curriculum Vitae



Informații personale

NUME / Prenume TOMULEASA / Ciprian

Adresa

[REDACTED]

E-mail

ciprian.tomuleasa@umfcluj.ro

Naționalitate Român

Ziua de naștere

[REDACTED]

Sex

masculin

Experiență de muncă

Perioada 2017– prezent

Poziția Medic specialist hematolog

Numele angajatorului Departamentul de Hematologie, Institutul Oncologic Ion Chiricuta, Cluj Napoca, Romania.

Perioada 2017 – prezent

Poziția Sef de Lucrari

Numele angajatorului Catedra de Hematologie, Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj Napoca, Romania

Perioada 2020 – prezent

Poziția Cercetator Stiintific II

Numele angajatorului Centrul de Genomica Functionala si Medicina Experimentală, Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj Napoca, Romania

Perioada 2015 – 2020

Poziția Cercetator Stiintific III

Numele angajatorului Centrul de Genomica Functionala si Medicina Experimentală, Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj Napoca, Romania

AL

Perioada	2013 – 2016
Poziția	Medic Rezident Hematolog
Numele angajatorului	Departamentul de Hematologie, Institutul Oncologic Ion Chiricuta, Cluj Napoca, Romania
Perioada	2013 – 2015
Poziția	Medic cercetator
Numele angajatorului	Centrul de Genomica Functionala si Medicina Experimentala, Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj Napoca, Romania
Perioada	2011 – 2013
Poziția	Cercetator postdoctoral
Numele angajatorului	Department of Internal Medicine, Division of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Perioada	2009 – 2011
Poziția	Asistent Cercetare
Numele angajatorului	Catedra de Histologie, Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj Napoca, Romania
Perioada	2007 – 2011
Poziția	Asistent Cercetare
Numele angajatorului	Laboratorul de Imunologie, Institutul Oncologic Ion Chiricuta, Cluj Napoca, Romania

Educație și training

Perioada	2016
Titlul calificării	Clinical Research Training in Hematology - Training in clinical research and clinical trials
Numele organizației care a realizat educația / training-ul	European Hematology Association
Perioada	2013 – 2016
Titlul calificării	Rezidentiat in hematologie
Numele organizației care a realizat educația / training-ul	Departamentul de Hematologie, Institutul Oncologic Ion Chiricuta, Cluj Napoca, Romania
Perioada	2015 – 3 luni
Titlul calificării	Training in Transplantul Alogen de Celule Stem Hematopoitice
Numele organizației care a realizat	

educația / training-ul		Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
	Perioada	2014 – 3 luni
	Titlul calificării	Training in Transplantul Haploidentic de Celule Stem Hematopoietice
Numele organizației care a realizat educația / training-ul		Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
	Perioada	2011 – 2013
	Titlul calificării	Cercetare postdoctorala in medicina interna
Numele organizației care a realizat educația / training-ul		Department of Internal Medicine, Division of Gastroenterology/ Hepatology The Johns Hopkins University School of Medicine, Baltimore, MD, USA
	Perioada	2011 – 2013
	Numele calificării	Diploma doctor
Numele organizației care a realizat educația / training-ul		Catedra de Imunologie, Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj Napoca Romania
	Perioada	2005 – 2011
	Numele calificării	Diploma medic
Numele organizației care a realizat educația / training-ul		Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj Napoca, Romania
	Perioada	2001 - 2005
	Titlul calificării	Diploma bacalaureat
Numele organizației care a realizat educația / training-ul		Colegiul National Calistrat Hogas, Piatra Neamt, Romania

**Subiecte de interes în
medicină translațională și
medicină clinică**

- Malignități hematologice
- Transplant de celule stem
- Cancere cu punct de plecare neprecizat
- Cancere rare

**Realizări
importante în medicină**

Index Hirsch: 26

- Prima izolare a unei linii de celule stem tumorale din Romania, in Martie 2010, ca si student in anul III – Medicina Generala (**Tomuleasa C**, Soritau O, Rus-Ciuca D, et al. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis. 2010; 19(1):61-7).

- Parte din echipa ce a realizat primul transplant haploidentic de celule stem hematopietice, ca si medic resident anul III (Tanase A, **Tomuleasa C**, Colita A, Ciurea SO. Haploidentical donors: can fast transplantation be life-saving for patients with advanced disease? Acta Haematologica 2016, in press , Tanase A, **Tomuleasa C**, Colita A, Ciurea SO. First successful haploidentical stem cell transplantator Romania. Rom J Intern Med 2016, in press).

**Membru în echipe de cercetare
medicală**

Perioada	2008 – prezent
Societatea	American College of Physicians 2014 – prezent
Perioada	European Hematology Association
Societatea	
Perioada	2014 – prezent
Societatea	American Society of Hematology
Perioada	2008 – prezent
Societatea	Societatea Romana de Oncologie si Radioterapie Medicala
Perioada	2013 – prezent
Societatea	Societatea Romana de Hematologie
Perioada	2016 - prezent
Societatea	Membru Fondator al Societatii Romane de Transplant Medular (membru in Comitetul Executiv)

și funcția

Cursuri și workshop-uri internaționale de calificare

- 
1. Clinical Management of Patients with End Stage Liver Disease (Barcelona, Spain, November 6-7, 2015)
 2. Molecular Diagnostics in Cancer Research, (Rome, Italy, November 29-30, 2014)
 3. Young Scientist representing Romania at the Lindau Nobel Prize Meeting in Medicine or Physiology (Lindau, Germany, July 1-7, 2014)
 4. Visiting Physician – Department of Cancer Medicine, Division of Stem Cell Transplantation - University of Texas MD Anderson Cancer Center, Houston, United States of America (Houston, TX, USA, July 1st - October 1st, 2014)
 5. Visiting Scientist– Department of Clinical Medicine - University of Bergen (Bergen, Norway, February 18-28, 2014)
 6. Visiting Physician– Department of Hematology and Oncology - Giovanni Paolo II Cancer Center / University of Bari (Bari, Italy, July 1-30, 2013)
 7. Molecular Diagnostics in Clinical Oncology, (Viareggio, Italy, November 29-30, 2013)
 8. EASL Masterclass on Hot Topics in Hepatology (Bordeaux, France, November 15-16, 2013)
 9. 5th Clinical Oncology Update (Krakow, Poland, May 10-12, 2013)
 10. EASL Basic Course on Hepatology Course VIII. Stem Cells and the Liver (Edinburgh, United Kingdom, February 8-9, 2013)
 11. EASL School of Hepatology Course XIX. Diagnosis of Liver Tumors (Bologna, Italy, June 7-9, 2012)
 12. EASL School of Hepatology Course XVI. Clinical Management of Hepatocellular Carcinoma (Jerusalem, Israel, June 5-6, 2011)
 13. Visiting Student - Division of Gastroenterology at Hepatology, Johns Hopkins University School of Medicine (Baltimore, MD, USA, August 1st- October 1st, 2010)
 14. 7th European School of Oncology - ESMO Course on Oncology for Medical Students (Ioannina, Greece, July 24-30, 2010)
 15. Europe Cancer Organisation Elective Course in Oncology for Medical Students (Poznań, Poland, August 11-21, 2009)
 16. 1st Masterclass on Intraabdominal Metastatic Cancer (Cluj Napoca, Romania, June 5-11, 2009)
 17. Organization of European Cancer Institutes Pathobiology Workshop: Structure and Genetics the New Paradigm (Cluj Napoca, Romania, October 24-25, 2008)

1. Student of the Year 2011 in Medicine National Award given by the Romanian Ministry of Education and Research
2. Ursus Award. Student Researcher of the Year 2009. Award given by the University of Medicine and Pharmacy to the student with the best research activity in 2009
3. Best Poster Presentation Award
2nd European Medical Students' Association Annual Congress, Antwerp, Belgium
4. Ali Khalifa Award. 3rd Oral Presentation Prize
16th Annual International Ain Shams Medical Students' Congress, Cairo, Egypt
5. Award Certificate for the Best Young Researcher
10th Congress of the Romanian Society for Physiological Sciences, Cluj-Napoca, Romania
6. Best Poster Presentation Award
12th National Congress for Medical Students and Young Doctors, Bucharest, Romania
7. 1st Oral Presentation Prize on Internal Medicine
11th International Congress for Medical Students and Young Doctors
12. Best Poster Presentation Award
11th International Congress for Medical Students and Young Doctors

Awards

Premii

17. Special Award or Young Oncologists 20th National Congress of Radiotherapy and Medical Oncology
18. Special Prize, for best presentation Iuliu Hatieganu University Science Symposium for Students, Cluj-Napoca, Romania
19. 2nd Oral Presentation Award for Fundamental Medicine 11th National Conference for Medical Students and Young Doctors, Bucharest, Romania
20. 3rd Oral Presentation Prize
International Science Congress for Medical Students, Young Doctors and Pharmacists Târgu Mureş, Romania

Grant-uri coordonate

1. "Nanotechnology approach in Acute Myeloid Leukemia management" – Nano-LAM. Grant Code: 14-SEE-PC-RO CLUJNAP03, Contract 1/16.01.2014.
Principal investigator: Andrei Cucuianu, for the Iuliu Hatieganu University of Medicine and Pharmacy (**Ciprian Tomuleasa - grant manager for the partner institution - Ion Chiricuta Oncology Institute**). Grant received after the Romania - European Economic Space (EES) International Research Grant Competition 2014-2016. **The value: 110.000 euro.**
2. "Cell and molecular mechanisms of primary myelofibrosis". Grant number contract 1492/1/28.01.2014.
Principal investigator: Ciprian Tomuleasa, for the Iuliu Hatieganu University of Medicine and Pharmacy. Internal Grant Competition of the Iuliu Hatieganu University of Medicine and Pharmacy, 2014-2015. **Value: 8.000 euro.**
3. "Innovative Nanoparticles-based Chemotherapy for Acute Myeloid Leukemia" - Nano-Chemotherapy. Grant Code: 15-SEE-PC-RO CLUJNAP03, Contract 1/25.06.2015.
Principal investigator: Ciprian Tomuleasa, for the Iuliu Hatieganu University of Medicine and Pharmacy. Grant received after the Romania–European Economic Space (EES) International Grant Competition 2015-2016. **Value: 41.000 euro.**
4. "Massively parallel high-throughput DNA sequencing for the identification of microRNAs differentially expressed between the metastatic site and the tissue of origin in cancers of unknown primary site" - CUP-miR. Grant Contract PN-II-RU-TE-2014-4-1783.
Principal investigator: Ciprian Tomuleasa, for the Iuliu Hatieganu University of Medicine and Pharmacy. Grant received after the Young Research Team Competition awarded by the Romanian Research Ministry and Education 2016-2017.
Value: 125.000 euro.
5. "A synthetic lethality approach in the acute myeloid leukaemia chemotherapy: PARP inhibitors plus anthracycline plus decitabine vs anthracycline plus decitabine –in vitro efficacy testing". Grant number contract 4995/10/08/03.2016
Principal investigator: Grigore Gafencu (grant mentor for Grigore Gafencu) , for the Iuliu Hatieganu University of Medicine and Pharmacy. Internal Grant Competition of the Iuliu Hatieganu University of Medicine and Pharmacy, 2015-2016.
Value: 2.000 euro.
6. "The efficacy of pirfenidone in primary myelofibrosis". Grant number contract
Principal investigator: Sonia Selicean (grant mentor for Sonia Selicean) , for the Iuliu Hatieganu University of Medicine and Pharmacy. Internal Grant Competition of the Iuliu Hatieganu University of Medicine and Pharmacy, 2016-2017.
Value: 2.000 euro.
7. "Non-invasive biomarkers for graft versus host disease following bone marrow hematopoietic stem cell transplantation". Grant number 57 BM/2016
Principal investigator: Ciprian Tomuleasa, for the Iuliu Hatieganu University of

Medicine and Pharmacy. Grant received after the Romania - P.R. China bilateral collaboration competition 2016-2017.

Value: 9533 euro.

Alte limbi
Autoevaluare
European level (*)
English
French

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
advanced	advanced	advanced	advanced	advanced
medium	medium	medium	medium	medium

Participare activă cu prezentare orală sau poster

Evenimente științifice naționale: 34 congrese

Evenimente științifice internaționale 39 congrese în Australia (Melbourne), Austria (Vienna), Belgiu (Antwerp), Croatia (Zagreb), Cyprus (Nicosia), Czech Republic (Brno), Denmark (Copenhagen), Egypt (Cairo), France (Angers, Bordeaux, Champéry, Paris), Germany (Berlin), Greece (Ioannina), Hungary (Budapest, Pecs, Szeged), Germany (Berlin, Jena, Lindau), Italy (Bologna, Rome, Viareggio), Lithuania (Druskininkai), Poland (Poznan, Krakow), Portugal (Falesia), Romania (Bucharest, Cluj Napoca, Ias Poiana Brasov, Predeal, Sinaia, Timisoara), Russia (Moscow), Serbia (Novi Sad), South Africa (Stellenbosch), Spain (Barcelona, Madrid, Valencia), Switzerland (Geneva), The Netherlands (Amsterdam), United Kingdom of Great Britain (Edinburgh, London) and United States of America (Boston, Baltimore, Houston, Orlando, San Diego, San Francisco).

Experiență în trial-uri clinice

1. **QuANTUM-R study**, a clinical trial for patients with FLT3-IDT positive acute myeloid leukemia that has relapsed or has failed to respond to initial chemotherapy. **Study sponsor: Daiichi-Sankyo.** Role in the study: **Co-investigator** for Ion Chiricută
Oncology Institute Cluj Napoca (Principal investigator: Dr. Delia Dima)

Organizarea evenimentelor științifice:

2015, septembrie 11, Cluj Napoca, Romania: **Nanotechnology in leukemia chemotherapy - Congress president**

Speakers: Professor Emmet McCormack, University of Bergen, Norway
Professor Simion Astilean, Babes Bolyai University, Romania
Dr. Cristian Berce, Iuliu Hatieganu University, Romania
Professor Anca Bojan, Iuliu Hatieganu University, Romania

2016, martie 11-12, Cluj Napoca, Romania: **Insights in hematology, 1st edition - Congress president**

Speakers: Professor Emmet McCormack, University of Bergen, Norway
Professor Gabriel Ghiaur, Johns Hopkins University, Baltimore, USA
Professor Stefan Ciurea, MD Anderson Cancer Center, Houston USA

Professor Shigeo Fuji, National Cancer Center, Tokyo, Japan
Professor Ravnit Grewal, Stellenbosch University, Cape Town, South Africa
Professor Akin Abayomi, Stellenbosch University, Cape Town, South Africa
Professor Alina Tanase, Fundeni Clinical Institute, Bucharest, Romania
Professor Anca Bojan, Iuliu Hatieganu University, Romania
Dr. Adrian Trifa, Iuliu Hatieganu University, Romania
Dr. Delia Dima, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

Publicații: Cărți:

1. NANOPHARMACOLOGY IN LEUKEMIA CHEMOTHERAPY. Andrei Cucuianu, **Ciprian Tomuleasa**, Anca Bojan, Cristian Berce, Simion Astilean, Emmet McCormack. Editura Cartea Ardeleana, Cluj Napoca, 2015.
2. CHIMIOTERAPIE HEMATOLOGICA. **Ciprian Tomuleasa**, Mariana Patiu, Anca Bojan, Mihnea Zdrenghea, Cristian Berce, Ioana Frinc, Bobe Petrushev, Delia Dima, George Calin, Alina Tanase, Stefan Ciurea. Editura Cartea Ardeleana, Cluj Napoca, 2016.
3. HEMATOLOGIA IN IMAGINI. Delia Dima, Mariana Patiu, Anca Bojan, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, Cluj Napoca, 2016.
4. LEUCEMIA MIELOIDA CRONICA. DE LA TERAPIA CU INHIBITORI DE TIROZIN KINAZE LA TRANSPLANT. **Ciprian Tomuleasa**, Delia Dima, Adrian Trifa. Editura Cartea Ardeleana, Cluj Napoca, 2017.

Cpitole de carte:

Internaționale:

1. TYPES OF RESEARCH DESIGNS. Fedor Moissenko, Cornelia Braicu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. In "CANCER RESEARCH AND CLINICAL TRIALS IN DEVELOPING COUNTRIES". Springer Science Books, ISBN 978-3-319-18443-2, Cape Town, South Africa 2016.

2. THEORETICAL MODELS OF HEMATOPOIETIC CELL DYNAMICS RELATED TO BONE MARROW TRANSPLANTATION. Radu Precup, Delia Dima, **Ciprian Tomuleasa**, Marcel Adrian Serban, Lorand Parajdi. In "Frontiers in Stem Cell and Regenerative Medicine Research". Betham Science Publishers, ISBN ..., 2017.

3. NON CODING RNAS IN LUNG CANCER ANGIOGENESIS. Cornelia Braicu, **Ciprian Tomuleasa**, Diana Gulei, George Adrian Calin, Ioana Berindan-Neagoe. In "Angiogenesis" Intech, ISBN ..., 2017.

Naționale:

1. CORELATII CLINICO-GENETICO-MOLECULARE IN ONCO-HEMATOLOGIE. **Ciprian Tomuleasa**, Delia Dima. In "PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE". Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.

2. ROLUL PROGNOTIC AL CITOGENETICII SI AL BIOLOGIEI MOLECULARE IN TRANSPLANTUL AUTOLOG DE CELULE STEM HEMATOPOIETICE. **Ciprian Tomuleasa**, Delia Dima, Alina Tanase. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.

3. REGIMURI DE CONDITIONARE. Alina Tanase, **Ciprian Tomuleasa**. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.

Publicații in extenso:

Lucrări originale în jurnale indexate internaționale:

1. FUNDS TO HELP EASTERN EUROPE CLOSE THE GAP. Cristian Berce, Radu Meza, **Ciprian Tomuleasa**. Nature, accepted for publication. **impact factor: 38.138**.

2. THE INTERPLAY BETWEEN CANCER CELLS, MACROPHAGES AND NATURAL KILLER CELLS MAY ACTUALLY DECIDE THE OUTCOME OF THERAPY WITH SORAFENIB. **Tomuleasa C**, Giannelli G, Cucuianu A, Aldea M, Paradiso A, Berindan-Neagoe I. Hepatology. 2014 Jul;60(1):430. **impact factor: 12.008**.

3. HUMAN BILE CONTAIN MICRORNA-LADEN EXOSOMES THAT CAN BE USED FOR CHOLANGIOCARCINOMA DIAGNOSIS. Ling Li, David Masica, Masaharu Ishida, **Ciprian**

Tomuleasa, Sho Umegaki, Anthony N. Kalloo, Christos Georgiades, Vikesh K. Singh, Mouen Khashab, Stuart Amateau, Zhiping Li, Patrick Okolo, Anne-Marie Lennon, Payal Saxena, Jean-Francois Geschwind, Todd Schlachter, Kelvin Hong, Timothy M. Pawlik, Marcia Canto, Joanna Law, Reem Sharaiha, Clifford R. Weiss, Haoran Peng, Paul Thuluvath, Michael Goggins, Eun Ji Shin, Vivek Kumbhari, Susan Hutfless, Liya Zhou, Esteban Mezey, Stephen J. Meltzer, Rachel Karchin, Florin M. Selaru. *Hepatology*. 2014;60(3):896-907. **impact factor: 12.008.**

4. DIVINE MESSENGERS: ARE EXOSOMES THE HERMESES OF MODERN MOLECULAR ONCOLOGY ? **Ciprian Tomuleasa**, Cornelia Braicu, Pamela Monroig, Andrei Cucuianu, Ioana Berindan-Neagoe, George A. Calin. *Cell Death Differentiation*. 2015; 22(1):34-45. **impact factor: 8.371.**

5. NANOMEDICINE FOR ACUTE LYMPHOBLASTIC LEUKEMIA DETECTION AND TREATMENT. Andra Sorina Tatar, Timea Simon, Simion Astilean, **Ciprian Tomuleasa**, Sanda Boca. *Journal of Controlled Release*, in press. **impact factor: 8.407.**

6. THE ROLE OF MICRORNAS IN THE PATHOGENESIS OF HIV-RELATED LYMPHOMAS. Ravnit Grewal, Andrei Cucuianu, Carmen Swanepoel, Delia Dima, Bobe Petrushev, Bogdan Pop, Ioana Berindan-Neagoe, **Emmanuel Akin Abayomi**, Ciprian Tomuleasa. *Critical Reviews in Clinical Laboratory Sciences* 2015, 52(5):232-41. **impact factor: 7.00.**

7. PSEUDOGENE INTS6P1 REGULATES IT'S CONGNATE GENE INTS6 THROUGH COMPETITIVE BINDING OF MIR-17-5P IN HEPATOCELLULAR CARCINOMA. Haoran Peng, Masaharu Ishida, Atsushi Saito, Atsushi Kamiya, James P. Hamilton, Rongdang Fu, Alexandru V. Olaru, Fangmei An, Irinel Popescu, Razvan Iacob, Simona Dima, Sorin T. Alexandrescu, Razvan Grigorie, Anca Nastase, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Florin Graur, Florin Zaharia, Michael S. Torbenson, Esteban Mezey, Minqiang Lu, Florin M. Selaru. *Oncotarget* 2015; ;6(8):5666-77. **impact factor: 6.63.**

8. NOVEL INSIGHTS INTO TRIPLE-NEGATIVE BREAST CANCERS, THE EMERGING ROLE OF ANGIOGENESIS, AND ANTIANGIOGENIC THERAPY. Cornelia Braicu, Roxana Chiorean, Alexandru Irimie, Sergiu Chira, **Ciprian Tomuleasa**, Emilian Neagoe, Angelo Paradiso, Patriciu Achimas-Cadariu, Vladimir Lazar, Ioana Berindan-Neagoe. *Expert Reviews in Molecular Medicine*. accepted for publication. **impact factor: 5.71.**

9. MAGNETIC RESONANCE IMAGING-BASED DIAGNOSIS OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN A PATIENT WITH NON-HODGKIN'S LYMPHOMA FOLLOWING THERAPY WITH CYCLOPHOSPHAMIDE, HYDROXYDAUNORUBICIN, VINCRISTINE, PREDNISONE AND RITUXIMAB. Delia Dima, **Ciprian Tomuleasa**, Alexandru Irimie, Ioan Stefan Florian, Bobe Petrushev, Ioana Berindan-Neagoe, Andrei Cucuianu. *Cancer*. 2014;120(24):4005-6. **impact factor: 5.2.**

10. RESULTS OF A TWO-ARM PHASE II CLINICAL TRIAL USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN HAPLOIDENTICAL AND MISMATCHED UNRELATED DONORS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Sameh Gaballa, Isabell Ge, Riad El-Fakih, Jonathan E. Brammer, **Ciprian Tomuleasa**, Sa A. Wang, Dean Lee, Demetrios Petropoulos, Kai Cao, Gabriela Rondon, Julianne Chen, Aimee Hammerstrom, Lindsey Lombardi, Gheath Alatrash, Martin Korbling, Oran Betul, Partow Kebriaei, Sairah Ahmed, Nina Shah, Katyoun Rezvani, David Marin, Qaiser Bashir, Amin Alousi, Yago Nieto, Muzaffar Qazilbash, Chitra Hosing, Uday Popat, Elizabeth J. Shpall, Issa Khouri, Richard E. Champlin, Stefan O. Ciurea. *Cancer*, **impact factor 5.068**, accepted for publication.

11. GOLD NANOPARTICLES ENHANCE THE EFFECT OF TYROSIN KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA THERAPY. Bobe Petrushev, Sanda Boca, Timea Simon, Cristian Berce, Ioana Frinc, Delia Dima, Sonia Selicean, Grigore-Aristide Gafencu, Alina Tanase, Mihnea Zdrenghea, Adrian Florea, Sorina Suarasan, Liana Dima, Raluca Stanciu, Ancuta Jurj, Anca Buzoianu, Andrei Cucuianu, Simion Astilean, Alexandru Irimie, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. *International Journal of Nanomedicine*, accepted for publication. **impact factor: 4.383.**

12. IN VIVO ASSESSMENT OF BONE MARROW TOXICITY FOR GOLD NANOPARTICLE-BASED BIOCONJUGATES IN CRL:CD1(ICR) MICE. Cristian Berce, Ciprian Lucan, Bobe Petrushev, Sanda Boca, Mirela Miclean, Orsolya Sarpataki, Simion Astilean, Anca Buzoianu, **Ciprian Tomuleasa**, Anca Bojan. *International Journal of Nanomedicine*, in press. **impact factor: 4.383.**

13. NANOPHARMACOLOGY IN TRANSLATIONAL HEMATOLOGY AND ONCOLOGY. **Ciprian Tomuleasa**, Cornelia Braicu, Alexandra Irimie, Lucian Craciun, Ioana Berindan-Neagoe. *Int J Nanomedicine*. 2014;9:3465-79. **impact factor: 4.195.**

14. REVERSING CHEMORESISTANCE OF MALIGNANT GLIOMAS STEM CELLS USING GOLD NANOPARTICLES. Anamaria Orza, Olga Soritau, **Ciprian Tomuleasa**, Liliana Olenic, Adrian Florea, Ovidiu Pana, Ioan Bratu, Eموke Pall, Stefan Florian, Dan Casciano, Alexandru S. Biris. International Journal of Nanomedicine 2013, 8:1-14. **impact factor: 4.195**
15. SORAFENIB FOR THE TREATMENT OF SOLID MALIGNANCIES. WHAT ABOUT THE CANCER MICROENVIRONMENT ? **Tomuleasa C**, Cucuianu A, Aldea M, Berindan-Neagoe I. International Journal of Nanomedicine. 2013;8:4043-4. **impact factor: 4.195**
16. MRI-BASED IDENTIFICATION OF UNDIFFERENTIATED CELLS. LOOKING AT THE TWO FACES OF JANUS. **Tomuleasa C**, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A. International Journal of Nanomedicine 2014, 9:865-6. **impact factor: 4.195.**
17. DOSE INTENSITY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE THERAPY FOR PEDIATRIC CNS MALIGNANCIES. Seiji Kojima, Andrei Cucuianu, Yoshiyuki Takahashi, Ioana Berindan-Neagoe, Ioan Stefan Florian, **Ciprian Tomuleasa**. International Journal of Nanomedicine 2014, 9:3247-8. **impact factor: 4.195.**
18. SMALL MOLECULES AGAINST B-RAF (BRAF) VAL600GLU (V600E) SINGLE MUTATION. Florin Zaharie, Roxana Cojocneanu-Petric R, Mihai Muresan, Ioana Frinc, Delia Dima, Bobe Petrushev, Alina Tanase, Cristian Berce, Mariana Chitic, Ioana Berindan-Neagoe, Valentina Pileczki, Alexandru Irimie, **Ciprian Tomuleasa**. International Journal of Nanomedicine 2015, 9:3247-8. **impact factor: 4.195.**
19. SHOULD A MORE PERSONALIZED APPROACH BE APPLIED TO HEMATOPOIETIC STEM CELL TRANSPLANTATION? P Kongtim, R Rondon, J Chen, **C Tomuleasa**, RE Champlin, SO Ciurea. J Stem Cell Res and Ther 2015, 5:3. **impact factor: 3.81.**
20. OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR LYMPHOMA WITH MELPHALAN-BASED CONDITIONING. Jonathan E. Brammer, Issa Khouri, Sameh Gaballa, Paolo Anderlini, Sairah Ahmed, Celina Ledesma, **Ciprian Tomuleasa**, Chitra Hosing, Richard E. Champlin, Stefan O. Ciurea. Biology of Blood and Marrow Transplantation 2015, in press. **impact factor: 3.404.**
21. ANTIPROLIFERATIVE EFFECT OF NOVEL PLATINUM(II) AND PALLADIUM(II) COMPLEXES ON HEPATIC TUMOR STEM CELLS IN VITRO. Natalia Miklášova, Eva

Fischer-Fodor, Peter Lönnecke, **Ciprian Ionut Tomuleasa**, Piroska Virag, Maria Perde-Schrepler, Roman Mikláš, Luminita Silaghi-Dumitrescu, Evamarie Hey-Hawkins. *European Journal of Medicinal Chemistry* 2012, 49C:41-47. **impact factor: 3.27**

22. MICRORNA-21 INHIBITS SERPINI 1, A GENE WITH NOVEL TUMOR SUPPRESSIVE EFFECTS IN GASTRIC CANCER. Sumitaka Yamanaka, Alexandru V Olaru, Delgermaa Luvsanjav, Fangmei An, Zhe Jin, Rachana Agarwal, **Ciprian Tomuleasa**, Irinel Popescu, Sorin Alexandrescu, Delia Dima, Mihaela Chivu-Economescu, Elizabeth A. Montgomery, Michael Torbenson, Christine Vazquez, Stephen J Meltzer, Florin M Selaru. *Digestive and Liver Diseases*, 2012, 44(7):589-596. **impact factor: 3.05**

23. MICRORNAS FOR THE DIAGNOSIS OF GRAFT VERSUS HOST DISEASE. **Ciprian Tomuleasa**, Shigeo Fuji, Andrei Cucuianu, Markus Kapp, Sonia Selicean, Alina Tanase, Delia Dima, Bobe Petrushev, Valentina Pileczki, Ioana Berindan-Neagoe, Alexandru Irimie, Hermann Einsele. *Annals of Hematology* 2015, 94(7):1081-92. **impact factor: 2.866**.

24. DESIGN OF FLT3 INHIBITOR GOLD NANOPARTICLE CONJUGATES AS POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA. Timea Simon, **Ciprian Tomuleasa**, Anca Bojan, Ioana Berindan-Neagoe, Sanda Boca, Simion Astilean. *Nanoscale Research Letters* 2015, accepted for publication, **impact factor: 2.78**.

25. CLINICOPATHOLOGICAL ANALYSIS OF A CASE SERIES OF PERIPHERAL T-CELL LYMPHOMAS, NOT OTHERWISE SPECIFIED, OF LYMPHOEPITELIOID VARIANT (LENNER'S LYMPHOMA). A CENTRAL EUROPEAN SINGLE-CENTER STUDY. Grigore-Aristide Gafencu, Sonia Selicean, Bobe Petrushev, Andrei Cucuianu, Delia Dima, Ioana Frinc, Alexandru Irimie, Rares Buiga, Valentina Pileczki, Ioana Berindan-Neagoe, Cristian Berce, **Ciprian Tomuleasa**. *Human Pathology*, accepted for publication. **impact factor: 2.769**.

26. THE ROLE OF TGF- β IN TISSUE MICROENVIRONMENT: A POTENTIAL NEW THERAPEUTIC APPROACH IN HCC TREATMENT. Bhavna Rani, Yuan Cao, Andrea Malfettone, **Ciprian Tomuleasa**, Isabel Fabregat, Gianluigi Giannelli. *World Journal of Gastroenterology* 2014, 20(15):4128-4140. **impact factor: 2.547**.

27. REPOSITIONING METFORMIN IN CANCER: GENETICS, DRUG TARGETS AND NEW WAYS OF DELIVERY. Mihaela Aldea, Lucian Craciun, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Gabriel Kacso, Ioan-Stefan Florian, Carmen Crivii. *Tumour Biology*. 2014; 35(6):5101-10. **impact factor: 2.518**.

28. GELATIN COATED GOLD NANOPARTICLES AS CARRIERS OF FLT3 INHIBITOR DRUGS FOR ACUTE MYELOID LEUKEMIA TREATMENT. Sorina Suarasan, Timea Simon, Sanda Boca, **Ciprian Tomuleasa**, Simion Astilean. Chemical Biology and Drug Design, in press. **impact factor: 2.485.**

29. METFORMIN, ARSENIC TRIOXIDE, OLANZAPINE AND BETA-BLOCKERS AS NEW HORIZONS FOR GLIOBLASTOMA THERAPY. HAS TIME COME FOR CLINICAL TRIALS? Marco Carmignani, Mihaela Aldea, Olga Soritau, Anna Rita Volpe, Alexandru Irimie, Ioan-Stefan Florian, **Ciprian Tomuleasa**, Bobe Petrushev, Adriana Baritchii, Gianina Crisan, Guido Valle. Journal of biological regulators and homeostatic agents 2014, 28(1):1-15. **impact factor: 2.406.**

30. THE USE OF ROTATION TO FENTANYL IN CANCER-RELATED PAIN. Delia Dima, **Ciprian Tomuleasa**, Ioana Frinc, Sergiu Pasca, Lorand Magdo, Mihai Muresan, Ioana Berindan-Neagoe, Cosmin Lisencu, Alexandru Irimie, Mihnea Zdrenghea. Journal of Pain Research, accepted for publication. **impact factor: 2.363.**

31. BCR-ABL T315I MUTATION, A NEGATIVE PROGNOSTIC FACTOR FOR THE TERMINAL PHASE OF CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH FIRST AND SECOND LINE TYROSINE KINASE INHIBITORS, MIGHT BE AN INDICATOR OF ALLOGENEIC STEM CELL TRANSPLANTATION AS THE TREATMENT OF CHOICE. **Ciprian Tomuleasa**, Delia Dima, Ioana Frinc, Mariana Patiu, Bobe Petrushev, Andrei Cucuianu, Ioana Berindan-Neagoe. Leukemia and Lymphoma 2015, 56(2):546-7. **impact factor: 2.301.**

32. THE LAUREN CLASSIFICATION HIGHLIGHTS THE ROLE OF EPITHELIAL-TO-MESENCHYMAL TRANSITION IN CARCINOGENESIS: AN IMMUNOHISTOCHEMISTRY STUDY OF THE STAT3 AND ADHESION MOLECULES EXPRESSION. Sergiu Susman, Raphaelle Barnoud, Frederique Bibeau, Francesco Borini, Marc Pocard, **Ciprian Tomuleasa**, Jean-Christophe Sabourin. Journal of Gastrointestinal and Liver Diseases 2015, 24(1):77-83. **impact factor: 2.202.**

33. DO LYMPHOMAS HAVE AN AUTOIMMUNE BACKGROUND AND HOW CAN WE INCREASE THE SENSITIVITY OF THE DIAGNOSIS OF PRIMARY PANCREATIC LYMPHOMA WITH RELATIVELY SMALL SAMPLES ? **Ciprian Tomuleasa**, Emmanuel Akin-Abayomi, Delia Dima, Cristian Tefas, Alexandru Irimie, Bobe Petrushev, Ioana Frinc, Ravnit Grewal. Journal of Gastrointestinal and Liver Diseases 2015, 24(3):391-2. **impact factor: 2.202.**

34. EXOSOME-CARRIED MICRORNA-375 INHIBITS CANCER CELL PROGRESSION VIA BCL-2 BLOCKING IN COLON CANCER. Mihai-Stefan Muresan, Florin Zaharie, Bobe Petrushev, Cristian Berce, Grigore Gafencu, Sonia Selicean, Ancuta Jurj, Roxana Cojocneanu-Petric, Cosmin-Ioan Lisencu, Laura-Ancuta Pop, Valentina Pileczki, Dan Eniu, Mihai-Andrei Muresan, Roxana Zaharie, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Alexandru Irimie. Journal of Gastrointestinal and Liver Diseases 2015, accepted for publication. **impact factor: 2.202.**

35. HENOCH SCHONLEIN PURPURA AND CLOSTRIDIUM DIFFICILE INFECTION, A HEMATOLOGISTS' POINT OF VIEW. Delia Dima, **Ciprian Tomuleasa**, Mihnea Zdrenghea. Journal of Gastrointestinal and Liver Diseases, submitted for publication. **impact factor: 2.202.**

36. MANAGEMENT OF RENAL EXTRASKELETAL CHONDROSARCOMA. Vitalie Gherman, **Ciprian Tomuleasa**, Catalina Bungardean, Dan Vasile Stanca, Victor Dan Ona, Bogdan Feciche, Alexandru Irimie, Ioan Coman. BMC Surgery 2014, in press. **impact factor: 1.97.**

37. CHRONIC GRANULAMATOUS DERMATOSIS AS A PRESENTING SIGN FOR CUTANEOUS T-CELL LYMPHOMAS. Andrei Cucuianu, Bobe Petrushev, Doinita Crisan, Rares Buiga, Ana Maria Rosu, Delia Dima, **Ciprian Tomuleasa**. European Journal of Dermatology 2015, 25(2):210. **impact factor: 1.92.**

38. GOLD NANOPARTICLES CONJUGATED WITH CISPLATIN/ DOXORUBICINE/ CAPECITABINE LOWER THE CHEMORESISTANCE OF HEPATOCELLULAR CARCINOMA-DERIVED CANCER CELLS. **Ciprian Tomuleasa**, Olga Soritău, Anamaria Orza, Mircea Dudea, Bobe Petrushev, Ofelia Mosteanu, Sergiu Susman, Adrian Florea, Eموke Pall, Mihaela Aldea, Gabriel Kacso, Victor Cristea, Ioana Berindan-Neagoe, Alexandru Irimie. Journal of Gastrointestinal and Liver Diseases 2012, 21(2):187-196. **impact factor: 1.81**

39. ISOLATION AND CHARACTERIZATION OF HEPATIC CANCER CELLS WITH STEM LIKE PROPERTIES FROM HEPATOCELLULAR CARCINOMA, **Ciprian Tomuleasa**, Olga Soritău, Dan Rus Ciucă, Teodora Pop, Daniela Todea, Ofelia Moşteanu, Bogdan Pintea, Vasile Foris, Sergiu Suşman, Gabriel Kacsó, Alexandru Irimie, Journal of Gastrointestinal and Liver Diseases, 2010; 19(1):61-67. **impact factor: 1.81**

40. ALDH AS A TUMOR MARKER FOR PANCREATIC CANCER. **Ciprian Tomuleasa**, Ofelia Mosteanu, Sergiu Susman, Victor Cristea. Journal of Gastrointestinal and Liver Diseases 2011, 20(4):443-446. **impact factor: 1.81**

41. PARASITAEMIA AND HEMATOLOGICAL ALTERATIONS IN MALARIA-AFFECTED REFUGEES IN SOUTH AFRICA. Nonzwakazi Pretty Ntombela, Joyce Mahlako Tsoka-Gwegweni, Uchenna Okafor, Andrei Bibirigea, Alexandru Irimie, **Ciprian Tomuleasa**. South African Medical Journal 2015, accepted for publication. **impact factor: 1.712**
42. SORAFENIB FOR ADVANCED STAGE HEPATOCELLULAR CARCINOMA. **Ciprian Tomuleasa**, Victor Cristea, Alexandru Irimie. European Journal of Gastroenterology and Hepatology, 2012, 24(3):346-347. **impact factor: 1.66**
43. GOLD NANOPARTICLES CONJUGATED WITH RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. Sanda Boca, Ciprian Lucan, Ioana Frinc, Bobe Petrushev, Timea Simon, Cristian Berce, Grigore-Aristide Gafencu, Delia Dima, Alina Tanase, Sonia Selicean, Valentina Pileczki, Laura Pop, Adrian Florea, Alexandru Irimie, Simion Astilean, Anca Bojan, Ioana Berindan-Neagoe, Mihnea Zdrenghea, **Ciprian Tomuleasa**. Farmacia 2016, accepted for publication. **impact factor: 1.162**.
44. REDISTRIBUTION OF IRON TOWARDS DEPOSITS IN ERYTHROBLASTOPENIC ANEMIA AS A CONSEQUENCE OF DECREASED ERYTHROFERRONE PRODUCTION. Andrei Cucuianu, Mariana Patiu, Adrian P. Trifa, **Ciprian Tomuleasa**, Delia Dima. Medical Hypotheses 2014, 83(5):530-2. **impact factor: 1.054**.
45. HAPLOIDENTICAL DONORS: CAN FASTER TRANSPLANTATION BE LIFE-SAVING FOR PATIENTS WITH ADVANCED DISEASE ? Alina Tanase, **Ciprian Tomuleasa**, Alexandra Marculescu, Alexandru Bardas, Anca Colita, Carmen Orban, Stefan Octavian Ciurea. Acta Haematologica 2015, accepted for publication. **impact factor: 0.994**
46. THE IMPORTANCE OF MICRO-RNAS IN THE STROMAL-BREAST CANCER CELL INTERPLAY. Sergiu Susman, **Ciprian Tomuleasa**, Zsolt Fekete, Brunella Pilato, Alexandru Irimie, Ioana Berindan-Neagoe. Cancer Biomark. 2014;14(2-3):137-44. **impact factor: 0.972**
47. PARANEOPLASTIC SYNDROMES WITH CONNECTIVE TISSUE INVOLVEMENT. IT'S NOT ALWAYS LUPUS ! T Timis, C Berce, A Duarte-Garcia, B Petrushev, V Cristea, **C Tomuleasa**. Journal of the Balkan Union of Oncology 2012, 17:417-421. **impact factor: 0.76**

48. MESENCHYMAL STEM CELL IRRADIATION IN CULTURE ENGAGES DIFFERENTIAL EFFECT OF HYPERFRACTIONATED RADIOTHERAPY FOR HEAD AND NECK CANCERS, **C Tomuleasa**, V Foris, O Sorițău, T Dicu, E Páll, I Brie, G Kacsó, Journal of Balkanic Union of Oncology, 2010; 15(2):348-356. **impact factor: 0.76.**
49. FUNCTIONAL AND MOLECULAR CHARACTERIZATION OF GLIOBLASTOMA MULTIFORME DERIVED CANCER STEM CELLS, **C Tomuleasa**, O Sorițău, D Rus Ciucă, H Ioani, S Sușman, M Petrescu, T Timis, D Cernea, G Kacsó, A Irimie, IS Florian, Journal of Balkan Union of Oncology, 2010; 15(3):583-591. **impact factor: 0.76**
50. METFORMIN PLUS TEMOZOLOMIDE-BASED CHEMOTHERAPY AS ADJUVANT TREATMENT FOR WHO GRADE III AND IV MALIGNANT GLIOMAS. O Soritau, **C Tomuleasa**, M Aldea, B Petrushev, S Susman, D Gheban, H Ioani, A Cocis, A Irimie, G Kacso, IS Florian. Journal of the Balkan Union of Oncology, 2011, 16:282-289. **impact factor: 0.76**
51. ANTIDIABETIC PHARMACOLOGY, A LINK BETWEEN METABOLIC SYNDROME AND NEURO-ONCOLOGY? M Aldea, **C Tomuleasa**, B Petrushev, S Susman, G Kacso, A Irimie, IS Florian, O Soritau. Journal of the Balkan Union of Oncology, 2011, 16:409-413. **impact factor: 0.76**
52. CANCER STEM CELLS AND MALIGNANT GLIOMAS. FROM PATHOPHYSIOLOGY TO TARGETED MOLECULAR THERAPY, IS Florian, **C Tomuleasa**, O Soritau, T Timis, G Kacso, A Irimie. Journal of the Balkan Union of Oncology, 2011, 16:16-23. **impact factor: 0.76**
53. ARSENIC TRIOXIDE SENSITIZES CANCER STEM CELLS TO CHEMORADIOTHERAPY – A NEW APPROACH IN THE TREATMENT OF INOPERABLE GLIOBLASTOMA MULTIFORME, **C Tomuleasa**, O Soritau, G Kacso, E Fischer-Fodor, A Cocis, H Ioani, M Petrescu, T Timis, D Cernea, P Virag, A Irimie, IS Florian, Journal of the Balkan Union of Oncology, 2010, 15:758-762. **impact factor: 0.76**
54. THE COLORECTAL CANCER STEM-LIKE CELL HYPOTHESIS. A PATHOLOGIST'S POINT OF VIEW. S Susman, **C Tomuleasa**, O Soritau, D Rus-Ciuca, J-C Sabourin, F Bibeau, A Irimie, R Buiga. Journal of the Balkan Union of Oncology, 2012, 17(2):230-236. **impact factor: 0.76**
55. THE ROLE OF DEPRESSION AND NEUROIMMUNE AXIS IN THE PROGNOSIS OF CANCER PATIENTS. Mihaela Aldea, Lucian Craciun, **Ciprian Tomuleasa**, Carmen Crivii. Journal of the Balkan Union of Oncology 2014, 19(1):5-14. **impact factor: 0.76**

56. THE ANDROGEN RECEPTOR AS KEY PLAYER IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCERS. IMPLICATIONS FOR NEW TREATMENTS. Adina Nemes, **Ciprian Tomuleasa**, Gabriel Kacsó. Journal of the Balkan Union of Oncology 2014, 19(2): 357-364. **impact factor: 0.76**

57. MICRORNA-21 STIMULATES GASTRIC CANCER GROWTH AND INVASION BY INHIBITING THE TUMOR SUPPRESSOR EFFECTS OF PROGRAMMED CELL DEATH PROTEIN 4 AND PHOSPHATASE AND TENSIN HOMOLOG. Ling Li, Liya Zhou, Yuwen Li, Sanren Lin, **Ciprian Tomuleasa**. Journal of the Balkan Union of Oncology 2014, 19(1):228-236. **impact factor: 0.76.**

58. CANCER STEM –LIKE CELLS: THE DARK KNIGHTS OF CLINICAL HEMATOLOGY AND ONCOLOGY. Ioana Frinc, Mihai-Stefan Muresan, Florin Zaharie, Ljubomir Petrov, Cristian Berce, Alexandra Irimie, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**. Journal of the Balkan Union of Oncology 2014, 19(2): 328-335. **impact factor: 0.76.**

59. METFORMIN PLUS SORAFENIB - AN ASSOCIATION THAT HIGHLY IMPACTS TEMOZOLOMIDE-REZISTANT GLIOBLASTOMA STEM-LIKE CELLS. Mihaela Aldea, Bobe Petrushev, Olga Soritau, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Adriana Filip, Gabriela Chereches, Mihai Cenariu, Lucian Craciun, Corina Tatomir, Ioan-Stefan Florian, Carmen Crivii, Gabriel Kacso. Journal of the Balkan Union of Oncology 2014, 19(2): 502-511. **impact factor: 0.76.**

60. THE EFFECT OF ANAESTHETIC ON NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN (NGAL) LEVELS AFTER ROBOTIC SURGICAL ONCOLOGY. Orsolya Mihály, Attila-Zoltan Mihály, Vitalie Gherman, Florin Zaharie, Sorana Bolboacă, Ciprian Chira, Constantin Bodolea, **Ciprian Tomuleasa**, Alexandru Irimie, Ioan Coman, Daniela Ionescu. Journal of the Balkan Union of Oncology 2015, 20(1):317-24. **impact factor: 0.76.**

61. MICRORNAS IN LIVER MALIGNANCIES. BASIC SCIENCE APPLIED IN SURGERY. Mihai-Stefan Muresan, Florin Zaharie, Anca Bojan, Bobe Petrushev, Roxana Cojocneanu-Petric, Alexandru Irimie, Grigore Gafencu, Sonia Selicean, Cristian Tefas, Andreea Cioca, Cristian Berce, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Patriciu Achimas-Cadariu. Journal of the Balkan Union of Oncology 2015, 20(2):361-75. **impact factor: 0.76.**

62. EFFECTS OF Co GAMMA-RAYS ON HUMAN OSTEOPROGENITOR CELLS, **C.I. Tomuleasa**, V. Foris, Olga Sorițău, Emöke Páll, Eva Fischer-Fodor, V. Lung-Illes, Ioana Brie, Piroska Virág, Maria Perder-Schrepler, I.D. Postescu, Gabriela Cherecheș, Otilia Barbos, Corina Tatomir, Romanian Journal of Morphology and Embryology, 2009; 50(3):3-6.
63. PRIMUM NON NOCERE. IS STEM CELL RESEARCH READY FOR CLINICAL TRIALS ?, **Ciprian Tomuleasa**, Olga Sorițău, Sergiu Șuşman, Vasile Foris, Emöke Páll, Carmen Mișu, Journal of the European Medical Students Association, 2009; 4(4):33-38.
64. ARSENIC TRIOXIDE PLUS CISPLATIN/ INTERFERON α -2B/ DOXORUBICIN/ CAPECITABINE COMBINATION CHEMOTHERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA, **Ciprian Tomuleasa**, Olga Sorițău, Teodora Pop, Eva Fischer-Fodor, Ofelia Mosteanu, Bobe Petrushev, Sergiu Susman, Mihaela Aldea, Monica Acalovschi, Alexandru Irimie, Gabriel Kacsó. Hematology Oncology and Stem Cell Therapy, 2011, 4(2):60-66.
65. ENHANCED CHEMORESISTANCE AND TUMOUR SPHERE FORMATION AS A LABORATORY MODEL FOR PERITONEAL MICROMETASTASIS IN EPITHELIAL OVARIAN CANCER, Olga Sorițău, **CI Tomuleasa**, Emöke Páll, Piroska Virág, Eva Fischer-Fodor, Gabriela Cherecheș, Otilia Barbos, Corina Tatomir, G Kacsó, A Irimie, Romanian Journal of Morphology and Embryology, 2010, 51(2):3-6.
66. CELLULAR INTERACTIONS IN PROSTATE CANCER GENESIS AND DISSEMINATION. LOOKING BEYOND THE OBVIOUS, **C Tomuleasa**, G Kacsó, S Șuşman, Olga Sorițău, Carmen Mișu, A Irimie, Piroska Virág, Romanian Journal of Morphology and Embryology, 2010, 51(3):427-435.
67. PARANEOPLASTIC SYNDROMES AS KEY ELEMENTS OF DIFFERENTIAL DIAGNOSIS. Tanase Timis, Doru Tomesc, Bobe Petrushev, Claudiu Sas, Mihaela Aldea, **Ciprian Tomuleasa**. Journal of the European Medical Students Association, 2011, 6(1):7-12.
68. PLACENTAL STEM CELL DIFFERENTIATION INTO ISLETS OF LANGERHANS-LIKE GLUCAGON SECRETING CELLS. S Susman, Olga Soritau, D Rus-Ciuca, **C Tomuleasa**, VI Pop, Carmen Mihaela Mișu. Romanian Journal of Morphology and Embryology, 2010, 51(4):733-738.
69. PANCREATIC EXOCRINE ADULT CELLS AND PLACENTAL STEM CELLS CO-CULTURE. WORKING TOGETHER IS ALWAYS THE BEST WAY TO GO. S Susman, Olga

Soritau, D Rus-Ciuca, **C Tomuleasa**, R Buiga, D Mihiu, VI Pop, Carmen Mihaela Mihiu. Romanian Journal of Morphology and Embryology, 2011, 52(3 Suppl):999-1004.

70. METFORMIN PLUS PIAF COMBINATION CHEMOTHERAPY FOR HEPATOCELLULAR CARCINOMA. B. Petrushev, **C. Tomuleasa**, O. Soritau, M. Aldea, T. Pop, S. Susman, G. Kacso, I. Berindan-Neagoe, A. Irimie, V. Cristea. Experimental Oncology, 2012, 34(1):17-24.

71. ESTABLISHMENT OF AN EMBRYONIC STEM CELL LINE FROM BLASTOCYST STAGE MOUSE EMBRYOS. Emoke Pall, I Groza, M Cenariu, Olga Soritau, Elen Gocza, **C Tomuleasa**. Romanian Journal of Morphology and Embryology, 2011, 52(3 Suppl):1005-1010.

72. MINIMALLY INVASIVE ENUCLEATION WITH ZERO ISCHEMIA FOR MALIGNANCIES. THE CLUJ NAPOCA EXPERIENCE. Gherman V, **Tomuleasa C**, Irimie A, Coman I. American Journal of Case Reports 2013;14:511-2.

73. BICYTOPENIA AS A PARANEOPLASTIC SYNDROME FOR PSEUDOMYXOMA PERITONEI. HEMATOLOGIC MANIFESTATIONS OF A SUBTLE DISEASE. **Ciprian Tomuleasa**, Bobe Petrushev, Madalina Vedean, Alexandru Irimie, Florin Zaharie, Ana Maria Rosu, Delia Dima, Andrei Cucuianu, Ioana Frinc. International Journal of General Medicine 2015, 8:93-5.

74. FIRST SUCCESSFUL HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ROMANIA. Alina Tanase, **Ciprian Tomuleasa**, Alexandra Marculescu, Alexandru Bardas, Anca Colita, Carmen Orban, Stefan Octavian Ciurea. Romanian Journal of Internal Medicine 2016, accepted for publication.

75. PROCEEDINGS FROM THE 1ST INSIGHTS IN HEMATOLOGY SYMPOSIUM, CLUJ NAPOCA, ROMANIA MARCH 11-12, 2016. Anca Bojan, Ioana Berindan-Neagoe, Stefan Ciurea, Delia Dima, Shigeo Fuji, Gabriel Ghiaur, Ravnit Grewal, Emmet McCormack, Alina Tanase, Adrian Trifa, Ciprian Tomuleasa. Romanian Journal of Internal Medicine 2016, accepted for publication.


76. TRANSTHORACIC ULTRASONOGRAPHY FOR THE IMMUNOCOMPROMISED PATIENT. Ioana Frinc, Petru Ilies, Delia Dima, Alina Tanase, Ljubomir Petrov, Alexandru Irimie, Bobe Petrushev, Cristian Berce, Mihai-Stefan Muresan, Cosmin Lisencu, Ioana Berindan-Neagoe, Anca Bojan, **Ciprian Tomuleasa**. Romanian Journal of Internal Medicine, 2016, accepted for publication.

Papers in National Scientific Journals:

1. OSTEOBLAST DIFFERENTIATION AND IMMUNOCYTOCHEMICAL CHARACTERIZATION OF HUMAN MESENCHYMAL STEM CELLS, **Ciprian Tomuleasa**, Olga Sorițău, Vasile Foris, Valentin Lung-Illes, Ioana Brie, Piroska Virág, Eva Fischer-Fodor, Maria Perde-Schrepler, Corina Tatomir, Ion Dan Postescu, Gabriela Cherecheș, Doina Piciu, Journal of Radiotherapy & Medical Oncology, 2008; 4:199-205. 2. ISOLATION AND CULTIVATION OF MOUSE MESENCHYMAL STEM CELLS ON POLYPROPYLENIC SCAFFOLD, Pall Eموke, I. Groza, **Tomuleasa C**, Ober C, Daria Groza, Bulletin of Agricultural Sciences and Veterinary Medicine, 2008; 65:139-143. 3. THE BASIC IMMUNOLOGY OF STEM CELL TRAFFICKING AND CANCER METASTASIS, **Ciprian Tomuleasa**, Sergiu Șușman, Olga Sorițău, Emőke Páll, Dan Rus Ciucă, Ioana Brie, Carmen Mihu, Journal of Radiotherapy and Medical Oncology, 2009; 15(2):89-94. 4. RAT BONE MARROW MESENCHYMAL STEM CELL ISOLATION, CULTIVATION AND DIFFERENTIATION, Páll Emőke, IS Groza, Olga Sorițău, **Tomuleasa C**, Cenariu M, Daria Groza, Teodora Vlasiu, Cluj Veterinary Journal, 2009; 12(1):29-33. 5. ROLE OF BMP-4 IN MOUSE EMBRYONIC STEM CELL DIFFERENTIATION, Pall Eموke, Groza I, Sorițău Olga, Cenariu M, Daria Groza, **C Tomuleasa**, USAMV Iași Lucrari Stiintifice, 2009, 52(11):94-97. 6. ISOLATION OF MULTIPOTENT MESENCHYMAL STEM CELLS FROM HUMAN PLACENTA, Emőke Páll, Daria Groza, Ioan Ștefan Groza, Olga Sorițău, **Ciprian Tomuleasa**, Mihai Cenariu, Ioana Cristina Ilea, Cluj Veterinary Journal, 2009; 16(2):46-50. 7. DNA DAMAGE AND THE GOVERNING DYNAMICS OF STEM CELL RADIOBIOLOGY, **C I Tomuleasa**, V Foris, Olga Sorițău, Emőke Páll, T Dicu, V Lung Illes, Ioana Brie, G Kacsó, Annals of the Romanian Society for Cell Biology, 2009; 14(2):13-20. 8. COLORECTAL CANCER STEM CELLS, **Ciprian Tomuleasa**, Sergiu Șușman, Olga Sorițău, Dan Rus-Ciucă, Rareș Buigă, Alexandru Irimie, Gabriel Kacsó, Carmen Mihu, Journal of Radiotherapy and Medical Oncology, 2010; 17(4):52-58. 9. DEFYING HAYFLICK LIMIT. SPONTANEOUS IMMORTALISATION OF HepCSC CANCER STEM CELL LINE, **Ciprian Tomuleasa**, Teodora Pop, Olga Soritau, Ofelia Mosteanu, Dan Rus-Ciucă, Alexandru Irimie, Monica Acalovschi, Journal of Radiotherapy and Medical Oncology, 2010; 17(4):63-67. 10. EVALUATION OF MULTIPOTENT STEM CELLS FROM HUMAN PLACENTA. I Groza, Eموke Pall, Daria Groza, Olga Soritau, **C Tomuleasa**, M Cenariu, Ioana Cristina Ilea, Emilia Groza. Lucrari Stiintifice Med Vet Timisoara 2010, 43(2):9-14. 11. ISOLATION, CHARACTERISATION, PHENOTYPING AND DIFFERENTIATION OF STEM CELLS FROM RAT PLACENTA. Eموke Pall, I Groza, M Cenariu, Cristina Ilea, Olga Soritau, **Ciprian Tomuleasa**, Cristi Berce, Lucrari Stiintifice Iasi 2010, 53(12):141-147. 12. DIFFERENTIATION OF EMBRYONIC MOUSE STEM CELL LINES. Pall Eموke, Gocza Ellen, Soritau Olga, **C Tomuleasa**, Lichner Szuszanna, M Cenariu, I Groza. Annals of the Romanian Society for Cell

Biology 2010; 15(2):143-149.13. IN VITRO EMBRYONIC STEM CELL DIFFERENTIATION. Emoke Pall, Ioan Stefan Groza, Soritau Olga, Mihai Cenariu, Elen Gocza, **Ciprian Tomuleasa**, Cluj Veterinary Journal 2010; 17(1):18-23.

14. MECANISMELE FUNDAMENTALE ALE METASTAZARII SI REZISTENTEI LA POLICHIMIOTERAPIE IN CANCERELE PULMONARE [THE FUNDAMENTAL MECHANISMS OF METASTATIC SPREAD AND CHEMOTHERAPY RESISTANCE IN LUNG CANCER]. **Ciprian Tomuleasa**, Gabriel Kacso, Olga Soritau, Sergiu Susman, Bobe Petrushev, Mihaela Aldea, Rares Buiga, Alexandru Irimie. Pneumologia 2011, 60(2):99-103.15. STEM-LIKE CELLS IN COLORECTAL ONCOLOGY. **C Tomuleasa**, S Susman, Olga Soritau, Ofelia Mosteanu, Teodora Pop, B Petrushev, G Kacso, R Buiga, M Tantau, A Irimie. Romanian Journal of Internal Medicine 2011; 49(3):189-196.16. THE AXIS OF EVIL IN THE FIGHT AGAINST CANCER. B Petrushev, **C Tomuleasa**, S Susman, Olga Soritau, Mihaela Aldea, G Kacso, R Buiga, A Irimie. Romanian Journal of Internal Medicine 2011; 49(4):317-323.17. EFFECTS OF THE STATIC MAGNETIC FIELD ON STEM CELLS IN THE VICINITY OF A 1 TESLA MRI SYSTEM. Cristinel Marincas, Anca Butnaru, Olga Soritau, **Ciprian Tomuleasa**, Radu Ciupa, Carmen Miha. Proceedings of the 3rd International Conference of E-Health of Bioengineering 2011: 315-318.



Carti:

1. NANOPHARMACOLOGY IN LEUKEMIA CHEMOTHERAPY. Andrei Cucuianu, **Ciprian Tomuleasa**, Anca Bojan, Cristian Berce, Simion Astilean, Emmet McCormack. Editura Cartea Ardeleana, Cluj Napoca, 2015. ISBN 978-606-8699-74-5.

2. CHIMIOTERAPIE HEMATOLOGICA. **Ciprian Tomuleasa**, Mariana Patiu, Anca Bojan, Mihnea Zdrenghea, Cristian Berce, Ioana Frinc, Bobe Petrushev, Delia Dima, George Calin, Alina Tanase, Stefan Ciurea. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-30-7.

3. HEMATOLOGIA IN IMAGINI. Delia Dima, Mariana Patiu, Anca Bojan, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-69-7.

4. LEUCEMIA MIELOIDA CRONICA. DE LA TERAPIA CU INHIBITORI DE TIROZIN KINAZE LA TRANSPLANT. **Ciprian Tomuleasa**, Delia Dima, Adrian Trifa. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-98-7.

5. NEOPLASMELE MIELOPROLIFERATIVE. Cristina Bagacean, Iulia Berceanu, Delia Dima, Bogdan Fetica, Jean-Cristophe Ianotto, Mariana Patiu, Adrian Tempescul, **Ciprian Tomuleasa**, Adrian Trifa, Mihnea Zdrenghea. Sub redactia Mihnea Zdrenghea. Editura Casa Cartii de Stiinta, Cluj Napoca, 2017. ISBN 978-606-17-1135-2.

6. GHID DE TRANSPLANT MEDULAR. Alina Tanase, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, Cluj Napoca, 2017.

Capitole de carte:

Internationale:

1. TYPES OF RESEARCH DESIGNS. Fedor Moissenko, Cornelia Braicu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. In "CANCER RESEARCH AND CLINICAL TRIALS

IN DEVELOPING COUNTRIES". Springer Science Books, ISBN 978-3-319-18443-2, Cape Town, South Africa 2016.

2. THEORETICAL MODELS OF HEMATOPOIETIC CELL DYNAMICS RELATED TO BONE MARROW TRANSPLANTATION. Radu Precup, Delia Dima, Ciprian Tomuleasa, Marcel Adrian Serban, Lorand Parajdi. In "Frontiers in Stem Cell and Regenerative Medicine Research". Betham Science Publishers, 2017.

3. NON-CODING RNAS IN LUNG CANCER ANGIOGENESIS. Cornelia Braicu, Ciprian Tomuleasa, Diana Gulei, George Adrian Calin, Ioana Berindan-Neagoe. In "Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy", book edited by Dan Simionescu and Agneta Simionescu, ISBN 978-953-51-3024-6, Print ISBN 978-953-51-3023-9, 2017.

4. PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Mihnea Zdrenghea, Delia Dima, **Ciprian Tomuleasa**, Horia Bumbea, Cristina Bagacean. In " New Approaches to the Management of Primary and Secondary CNS Tumors is published " Intech, ISBN 978-953-51-3052-9, 2017.

5. THE USEFULNESS OF BIOMARKERS FOR DIAGNOSIS. Patric Teodorescu, Sergiu Pasca, **Ciprian Tomuleasa**. In "Pineal region lesions. Management strategies and controversial issues. Springer – Zurich, 2020, ISBN 978-3-030-50912-5.

Nationale:

1. CORELATII CLINICO-GENETICO-MOLECULARE IN ONCO-HEMATOLOGIE. **Ciprian Tomuleasa**, Delia Dima. In "PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE". Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.

2. ROLUL PROGNOSTIC AL CITOGENETICII SI AL BIOLOGIEI MOLECULARE IN TRANSPLANTUL AUTOLOG DE CELULE STEM HEMATOPOIETICE. **Ciprian Tomuleasa**, Delia Dima, Alina Tanase. In "AUTOTRANSPLANTUL DE CELULE STEM

HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.

3. REGIMURI DE CONDITIONARE. Alina Tanase, **Ciprian Tomuleasa**. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.

4. EVALUAREA CARDIACA PENTRU TRANSPLANTUL DE CELULE STEM HEMATOPOIETICE. **Ciprian Tomuleasa**, Sergiu Pasca, Anca Bojan, Delia Dima. In "MANUAL DE CARDIOONCOLOGIE". Cristina Vlad, Dan Radulescu, Simona Dragan, Claudia Burz. Editura Medicala Universitara Iuliu Hatieganu 2020.

Lista de articole științifice

1. Articole publicate in extenso în reviste și volumele unor manifestari științifice *indexate ISI, Web of Science, Core collection.*

a. Autor principal

Nr. Crt.	Titlul	Autorii	Calitatea autorului ¹	Revista, volum, nr. pagini	Factorul de impact ²	Quartil a	Anul ³
1	Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis	Tomuleasa C , Selicean S, Gafencu G, Petrushev B, Pop L, Berce C, Jurj A, Trifa A, Rosu AM, Pasca S, Magdo L, Zdrenghea M, Dima D, Tanase A, Frinc I, Bojan A, Berindan-Neagoe I, Ghiaur G, Ciurea SO	<i>prim autor</i>	J Cell Physiol., 233(1):422-433	4.522	Q1	2018
2	Cutaneous wound healing using polymeric surgical dressings based on chitosan, sodium hyaluronate and resveratrol. A preclinical experimental study	Berce C, Muresan MS, Soritau O, Petrushev B, Tefas L, Rigo I, Ungureanu G, Catoi C, Irimie A, Tomuleasa C .	<i>ultim autor</i>	Colloids Surf B Biointerfaces., 163:155-166	3.973	Q1	2018
3	Hodgkin's lymphoma and its association with EBV and HIV infection	Grewal R, Irimie A, Naidoo N, Mohamed N, Petrushev B, Chetty M, Tomuleasa C , Abayomi EA	<i>autor corespondent</i>	Crit Rev Clin Lab Sci, 55(2):102-114	4.817	Q1	2018
4.	Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia	Tomuleasa C , Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, Kitano S.	<i>prim autor</i>	Front Immunol., 9:239.	5.511	Q1	2018
5.	The role of the pathology	Susman S, Berindan-Neagoe I,	<i>ultim autor</i>	Cancer Manag Res,	3.702	Q2	2018

	department in the preanalytical phase of molecular analyses.	Petrushev B, Pirlog R, Florian IS, Miha CM, Berce C, Craciun L, Grewal R, Tomuleasa C .		10:745-753			
6.	Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches	Tomuleasa C , Selicean C, Cismas S, Jurj A, Marian M, Dima D, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghea M, Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-Neagoe I.	<i>prim autor</i>	Crit Rev Clin Lab Sci, 55(5):329-345	4.817	Q1	2018
7.	Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome	Jurj A, Pop L, Petrushev B, Pasca S, Dima D, Frinc I, Deak D, Desmirean M, Trifa A, Fetica B, Gafencu G, Selicean S, Moisoiu V, Micu WT, Berce C, Sacu A, Moldovan A, Colita A, Bumbea H, Tanase A, Dascalescu A, Zdrenghea M, Stiufiuc R, Leopold N, Tetean R, Burzo E, Tomuleasa C , Berindan-Neagoe I.	<i>autor corespondent</i>	Crit Rev Clin Lab Sci., 55(7):501-515	4.817	Q1	2018
8.	Castleman's disease in the HIV-endemic setting	Mahroug ER, Sher-Locketz C, Desmirean MS, Abayomi EA, Tomuleasa C , Grewal R	<i>autor corespondent</i>	Cancer Manag Res.,10:4553-4563	3.702	Q2	2018
9.	Use of flow cytometry in the phenotypic diagnosis of hodgkin's lymphoma.	Grewal RK, Chetty M, Abayomi EA, Tomuleasa C , Fromm JR.	<i>autor corespondent</i>	Cytometry B Clin Cytom.;96(2):116-127	2.757	Q2	2018
10.	Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-	Zaharie F, Pop LA, Petrushev B, Jurj A, Muresan MS, Eniu D, Fetica B, Petkov B, Pasca S, Piciu D, Rus I, Deak D, Dima D, Desmirean MS, Tomuleasa C , Berindan-Neagoe I.	<i>autor corespondent</i>	Histol Histopathol.;34(6):663-670	1.777	Q2	2018

	cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient						
11.	Persistent Basophilia May Suggest an "Accelerated Phase" in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia	Dobrowolski J, Pasca S, Teodorescu P, Selicean C, Rus I, Zdrenghea M, Bojan A, Trifa A, Fetica B, Petrushev B, Rosu AM, Berindan-Neagoe I, Tomuleasa C , Dima D	<i>autor corespondent</i>	Front Oncol. 6;9:872.	4.137	Q2	2018
12	Transient leukemia of Down syndrome.	Sas V, Blag C, Zaharie G, Puscas E, Lisencu C, Andronic-Gorcea N, Pasca S, Petrushev B, Chis I, Marian M, Dima D, Teodorescu P, Iluta S, Zdrenghea M, Berindan-Neagoe I, Popa G, Man S, Colita A, Stefan C, Kojima S, Tomuleasa C	<i>ultim autor</i>	Crit Rev Clin Lab Sci.;56(4):247-259	4.817	Q1	2019
13	Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician.	Constantinescu C, Bodolea C, Pasca S, Teodorescu P, Dima D, Rus I, Tat T, Achimas-Cadariu P, Tanase A, Tomuleasa C , Einsele H	<i>autor corespondent</i>	J Clin Med. 20;8(6).	5.688	Q1	2019
14	Approach to the Adult Acute Lymphoblastic Leukemia Patient.	Sas V, Moisoiu V, Teodorescu P, Tranca S, Pop L, Iluta S, Pasca S, Blag C, Man S, Roman A, Constantinescu C, Rus I, Buse M, Fetica B, Marian M, Selicean C, Berindan-Neagoe I, Petrushev B, Bumbea H, Tanase A, Zdrenghea	<i>autor corespondent</i>	J Clin Med. 6;8(8)	5.688	Q1	2019

		M, Fuji S, Kitano S, Tomuleasa C ; Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation					
15	LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation.	Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, Craciun OG, Soare D, Ghimici C, Manolache R, Gelatu I, Vladareanu AM, Pasca S, Teodorescu P, Dima D, Lupu A, Coriu D, Tomuleasa C , Tanase A.	<i>autor corespondent</i>	Front Oncol. 10;9:892.	4.137	Q2	2019
16	Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology	Moisoiu V, Teodorescu P, Parajdi L, Pasca S, Zdrenghea M, Dima D, Precup R, Tomuleasa C , Soverini S.	<i>autor corespondent</i>	Front Oncol. 23;9:863.	4.137	Q2	2019
17	KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma	Pasca S, Tomuleasa C , Teodorescu P, Ghiaur G, Dima D, Moisoiu V, Berce C, Stefan C, Ciechanover A, Einsele H	<i>autor corespondent</i>	Front Oncol. 24;9:1137.	4.137	Q2	2019

¹ se va nota (prim autor, autor corespondent, ultim autor, autor cu contribuții egale)

² se va nota factorul de impact în anul apariției articolului

³ se va nota anul apariției articolului

b. Coautor

Nr. Crt.	Titlul	Autorii	Revista, volum, nr. Pagini	Factorul de impact ²	Quartil a	Anul ³
1	MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients.	Trifa AP, Bănescu C, Bojan AS, Voina CM, Popa Ș, Vișan S, Ciubean AD, Tripon F, Dima D, Popov VM, Vesa ȘC, Andreescu M, Török-Vistai T, Mihăilă RG, Berbec N, Macarie I, Coliță A, Iordache M, Cătană AC, Farcaș MF, Tomuleasa C , Vasile K, Trucă C, Todincă A, Pop-Muntean L, Manolache R, Bumbea H, Vlădăreanu AM, Gaman M, Ciufu CM, Popp RA.	Am J Hematol., 93(1):100-106	6.137	Q1	2018
2.	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.	Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshoury T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C , Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girmita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA	Genome Res, 28(4):432-447	9.944	Q1	2018
3.	Modest contribution of JAK2 V617F allele burden to the occurrence of major	Trifa AP, Bănescu C, Voina CM, Popa Ș, Török-Vistai T, Bojan AS, Dima D, Zdrenghia M, Fetica B,	Blood Cells Mol Dis, 73:45-46	2.305	Q3	2018

	thrombosis in polycythemia vera and essential thrombocythemia	Vişan S, Tomuleasa C , Pârvu A, Urian L, Pop B, Popov VM, Andreescu M, Popp RA.				
4.	Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis	Selicean SE, Tomuleasa C , Grewal R, Almeida-Porada G, Berindan-Neagoe I.	Leuk Lymphoma, 60(4):876-885	2.674	Q2	2018
5	Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives	Bagacean C, Tomuleasa C , Tempescul A, Grewal R, Brooks WH, Berthou C, Renaudineau Y.	Crit Rev Clin Lab Sci. 56(5):321-332	4.817	Q1	2019
6	CD19-targeted, Raman tagged gold nanourchins as theranostic agents against acute lymphoblastic leukemia	Tatar AS, Jurj A, Tomuleasa C , Florea A, Berindan-Neagoe I, Cialla-May D, Popp J, Astilean S, Boca S.	Colloids Surf B Biointerfaces. 1;184:110478	3.973	Q2	2019
7	Long Non-coding RNAs in Myeloid Malignancies	Zimta AA, Tomuleasa C , Sahnoune I, Calin GA, Berindan-Neagoe I	Front Oncol. 18;9:1048.	4.137	Q2	2019
8	SERS assessment of the cancer-specific methylation pattern of genomic DNA: towards the detection of acute myeloid leukemia in patients undergoing hematopoietic stem cell transplantation	Moisoiu V, Stefanu A, Iancu SD, Moisoiu T, Loga L, Dican L, Alecsa CD, Boros I, Jurj A, Dima D, Bagacean C, Tetean R, Burzo E, Tomuleasa C , Elec F, Leopold N.	Anal Bioanal Chem.;411(29):7907-7913	3.286	Q2	2019

¹ se va nota (prim autor, autor corespondent, ultim autor, autor cu contribuții egale)

² se va nota factorul de impact în anul apariției articolului

³ se va nota anul aparitiei articolului

2. Articole publicate in extenso în reviste și volumele unor manifestari științifice *indexate BDI*

c. Autor principal

Nr. Crt.	Titlul	Autorii	Calitatea autorului ¹	Revista, volum, nr. pagini	Anul ²
1	Paraneoplastic hypereosinophilia in a patient with peripheral T cell lymphoma, not otherwise specified.	Desmirean M, Deak D, Rus I, Dima D, Iluta S, Preda A, Moldovan T, Roman A, Tomuleasa C , Petrushev B	autor corespondent	Med Pharm Rep. ;92(4):421-426	2019

¹ se va nota (prim autor, autor corespondent, ultim autor, autor cu contribuții egale)

² se va nota anul aparitiei articolului

a. Coautor

Nr. Crt.	Titlul	Autorii	Revista, volum, nr. pagini	Anul ²

² se va nota anul aparitiei articolului

3. Alte articole

Nr. Crt.	Titlul	Autorii	Calitatea autorului ¹	Revista, volum, nr. pagini	Anul ²
-	-	-	-	-	-

¹ se va nota (prim autor, autor corespondent, ultim autor, autor cu contribuții egale, coautor)

² se va nota anul aparitiei articolului

4. Articole ISI (Web of Science, Core collection) in extenso de la ultima promovare

Nr. Crt.	Titlul	Autorii	Calitatea autorului ¹	Revista, volum, nr. pagini	Factorul de impact ²	Quartila	Anul ³
1	Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis	Tomuleasa C , Selicean S, Gafencu G, Petrushev B, Pop L, Berce C, Jurj A, Trifa A, Rosu AM, Pasca S, Magdo L, Zdrenghea M, Dima D, Tanase A, Frinc I, Bojan A, Berindan-Neagoe I, Ghiaur G, Ciurea SO	<i>prim autor</i>	J Cell Physiol., 233(1):422-433	4.522	Q1	2018
2	Cutaneous wound healing using polymeric surgical dressings based on chitosan, sodium hyaluronate and resveratrol. A preclinical experimental study	Berce C, Muresan MS, Soritau O, Petrushev B, Tefas L, Rigo I, Ungureanu G, Catoi C, Irimie A, Tomuleasa C .	<i>ultim autor</i>	Colloids Surf B Biointerfaces., 163:155-166	3.973	Q2	2018
3	Hodgkin's lymphoma and its association with EBV and HIV infection	Grewal R, Irimie A, Naidoo N, Mohamed N, Petrushev B, Chetty M, Tomuleasa C , Abayomi EA	<i>autor corespondent</i>	Crit Rev Clin Lab Sci, 55(2):102-114	4.817	Q1	2018
4.	Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia	Tomuleasa C , Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, Kitano S.	<i>prim autor</i>	Front Immunol., 9:239.	5.511	Q1	2018
5.	The role of the pathology department in the preanalytical phase	Susman S, Berindan-Neagoe I, Petrushev B, Pirlog R, Florian IS, Miha CM, Berce C, Craciun L, Grewal R,	<i>ultim autor</i>	Cancer Manag Res, 10:745-753	3.702	Q2	2018

	of molecular analyses.	Tomuleasa C.					
6.	Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches	Tomuleasa C , Selicean C, Cismas S, Jurj A, Marian M, Dima D, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghea M, Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-Neagoe I.	<i>prim autor</i>	Crit Rev Clin Lab Sci, 55(5):329-345	4.817	Q1	2018
7.	Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome	Jurj A, Pop L, Petrushev B, Pasca S, Dima D, Frinc I, Deak D, Desmirean M, Trifa A, Fetica B, Gafencu G, Selicean S, Moisoiu V, Micu WT, Berce C, Sacu A, Moldovan A, Colita A, Bumbea H, Tanase A, Dascalescu A, Zdrenghea M, Stiufiuc R, Leopold N, Tetean R, Burzo E, Tomuleasa C , Berindan-Neagoe I.	<i>autor corespondent</i>	Crit Rev Clin Lab Sci., 55(7):501-515	4.817	Q1	2018
8.	Castleman's disease in the HIV-endemic setting	Mahroug ER, Sher-Locketz C, Desmirean MS, Abayomi EA, Tomuleasa C , Grewal R	<i>autor corespondent</i>	Cancer Manag Res.,10:4553-4563	3.702	Q2	2018
9.	Use of flow cytometry in the phenotypic diagnosis of hodgkin's lymphoma.	Grewal RK, Chetty M, Abayomi EA, Tomuleasa C , Fromm JR.	<i>autor corespondent</i>	Cytometry B Clin Cytom.;96(2):116-127	2.757	Q2	2018
10.	Next-generation sequencing-based characterization of	Zaharie F, Pop LA, Petrushev B, Jurj A, Muresan MS, Eniu D, Fetica B, Petkov B, Pasca S,	<i>autor corespondent</i>	Histol Histopathol.;34(6):663-670	1.777	Q2	2018

	<p>the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma.</p> <p>Correlation between the genetic profile of the malignancy and the clinical outcome of the patient</p>	Piciu D, Rus I, Deak D, Dima D, Desmirean MS, Tomuleasa C , Berindan-Neagoe I.					
11.	<p>Persistent Basophilia May Suggest an "Accelerated Phase" in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia</p>	Dobrowolski J, Pasca S, Teodorescu P, Selicean C, Rus I, Zdrenghea M, Bojan A, Trifa A, Fetica B, Petrushev B, Rosu AM, Berindan-Neagoe I, Tomuleasa C , Dima D	<i>autor corespondent</i>	Front Oncol. 6;9:872.	4.137	Q2	2018
12	<p>Transient leukemia of Down syndrome.</p>	Sas V, Blag C, Zaharie G, Puscas E, Lisencu C, Andronic-Gorcea N, Pasca S, Petrushev B, Chis I, Marian M, Dima D, Teodorescu P, Iluta S, Zdrenghea M, Berindan-Neagoe I, Popa G, Man S, Colita A, Stefan C, Kojima S, Tomuleasa C	<i>ultim autor</i>	Crit Rev Clin Lab Sci.;56(4):247-259	4.817	Q1	2019
13	<p>Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-</p>	Constantinescu C, Bodolea C, Pasca S, Teodorescu P, Dima D, Rus I, Tat T, Achimas-Cadariu P, Tanase A, Tomuleasa C , Einsele H	<i>autor corespondent</i>	J Clin Med. 20;8(6).	5.688	Q1	2019

	Call Physician.						
14	Approach to the Adult Acute Lymphoblastic Leukemia Patient.	Sas V, Moisiu V, Teodorescu P, Tranca S, Pop L, Iluta S, Pasca S, Blag C, Man S, Roman A, Constantinescu C, Rus I, Buse M, Fetica B, Marian M, Selicean C, Berindan-Neagoe I, Petrushev B, Bumbea H, Tanase A, Zdrenghea M, Fuji S, Kitano S, Tomuleasa C ; Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation	<i>autor corespondent</i>	J Clin Med. 6;8(8)	5.688	Q1	2019
15	LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation.	Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, Craciun OG, Soare D, Ghimici C, Manolache R, Gelatu I, Vladareanu AM, Pasca S, Teodorescu P, Dima D, Lupu A, Coriu D, Tomuleasa C , Tanase A.	<i>autor corespondent</i>	Front Oncol. 10;9:892.	4.137	Q2	2019
16	Assessing Measurable Residual Disease in Chronic	Moisiu V, Teodorescu P, Parajdi L, Pasca S, Zdrenghea M, Dima D, Precup R,	<i>autor corespondent</i>	Front Oncol. 23;9:863.	4.137	Q2	2019

	Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology	Tomuleasa C , Soverini S.					
17	KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma	Pasca S, Tomuleasa C , Teodorescu P, Ghiaur G, Dima D, Moisoiu V, Berce C, Stefan C, Ciechanover A, Einsele H	<i>autor corespondent</i>	Front Oncol. 24;9:1137.	4.137	Q2	2019
18	MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms : A study on 939 patients.	Trifa AP, Bănescu C, Bojan AS, Voina CM, Popa Ș, Vișan S, Ciubean AD, Tripon F, Dima D, Popov VM, Vesa ȘC, Andreescu M, Török-Vistai T, Mihăilă RG, Berbec N, Macarie I, Coliță A, Iordache M, Cătană AC, Farcaș MF, Tomuleasa C , Vasile K, Truică C, Todincă A, Pop-Muntean L, Manolache R, Bumbea H, Vlădăreanu AM, Gaman M, Ciufu CM, Popp RA.	<i>coautor</i>	Am J Hematol., 93(1):100-106	6.137	Q1	2018
19	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations.	Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H,	<i>coautor</i>	Genome Res, 28(4):432-447	9.944	Q1	2018

		Tomuleasa C , Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA					
20	Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycythemia vera and essential thrombocythemia	Trifa AP, Bănescu C, Voina CM, Popa Ș, Török-Vistai T, Bojan AS, Dima D, Zdrenghea M, Fetica B, Vișan S, Tomuleasa C , Pârvu A, Urian L, Pop B, Popov VM, Andreescu M, Popp RA.	<i>coauthor</i>	Blood Cells Mol Dis, 73:45-46	2.305	Q3	2018
21	Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis	Selicean SE, Tomuleasa C , Grewal R, Almeida-Porada G, Berindan-Neagoe I.	<i>coauthor</i>	Leuk Lymphoma, 60(4):876-885	2.674	Q2	2018
22	Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives	Bagacean C, Tomuleasa C , Tempescul A, Grewal R, Brooks WH, Berthou C, Renaudineau Y.	<i>coauthor</i>	Crit Rev Clin Lab Sci. 56(5):321-332	4.817	Q1	2019
23	CD19-targeted, Raman tagged gold nanourchins as theranostic agents against acute lymphoblastic leukemia	Tatar AS, Jurj A, Tomuleasa C , Florea A, Berindan-Neagoe I, Cialla-May D, Popp J, Astilean S, Boca S.	<i>coauthor</i>	Colloids Surf B Biointerfaces. 1;184:110478	3.973	Q2	2019

24	Long Non-coding RNAs in Myeloid Malignancies	Zimta AA, Tomuleasa C , Sahnoune I, Calin GA, Berindan-Neagoe I	<i>coautor</i>	Front Oncol. 18;9:1048.	4.137		2019
25	SERS assessment of the cancer-specific methylation pattern of genomic DNA: towards the detection of acute myeloid leukemia in patients undergoing hematopoietic stem cell transplantation	Moisoiu V, Stefancu A, Iancu SD, Moisoiu T, Loga L, Dican L, Alecsa CD, Boros I, Jurj A, Dima D, Bagacean C, Tetean R, Burzo E, Tomuleasa C , Elec F, Leopold N.	<i>coautor</i>	Anal Bioanal Chem.;411(29):7907-7913	3.286	Q2	2019

¹ se va nota (prim autor, autor corespondent, ultim autor, autor cu contribuții egale, coautor)

² se va nota factorul de impact în anul apariției articolului

³ se va nota anul apariției articolului

5. Articole BDI in extenso de la ultima promovare

Nr. Crt.	Titlul	Autorii	Calitatea autorului ¹	Revista, volum, nr. pagini	Anul ²
1	Paraneoplastic hypereosinophilia in a patient with peripheral T cell lymphoma, not otherwise specified.	Desmirean M, Deak D, Rus I, Dima D, Iluta S, Preda A, Moldovan T, Roman A, Tomuleasa C , Petrushev B	<i>autor corespondent</i>	Med Pharm Rep. ;92(4):421-426	2019

¹ se va nota (prim autor, autor corespondent, ultim autor, autor cu contribuții egale, coautori)

² se va nota anul apariției articolului